Recent Press and News Releases
Venturis Therapeutics, Inc. Announces Affiliation With David G. Armstrong DPM MD PhD the Most Noted Authority on the Diabetic Foot
June 06, 2021
Venturis Therapeutics, Inc. Announces Strategic Alliance with Prevail InfoWorks, Inc. and Prevail Partners, LLC
September 09, 2021
Venturis Therapeutics Inc. Announces Granting of US Patent for the Angiogenic Treatment of Ischemic Heart Disease, issued April 6, 2021, with 15 Patent Claims
April 30, 2021
15 Dallas Biotech Companies turning the Lone Star State into a Life Sciences leader
July 06, 2020
Venturis Therapeutics, Inc. Announces its Applications for Four New Patents Related to the Use of Therapeutic Angiogenesis in the Treatment of Illnesses Related to the COVID - 19 Virus, as Well as Illnesses Related to Other Viruses
May 5, 2020
Venturis Therapeutics Inc. Announces Granting of U.S. and Australian Patents for the Therapeutic Angiogenesis in ErectileConditions
March 10, 2020
Venturis Therapeutics Inc. Announces Exclusive License Agreement with James Cook University in Queensland, Australia
February 25, 2020
Patents at the Core: the Biotech Business
January 20, 2020
Venturis Therapeutics -  A positive new chapter in the life of the Company
January 07, 2020
Venturis announces Granting of US Patent for the Therapeutic Angiogenesis in Erectile Conditions
October 18, 2019
Results of June 2019 Shareholders Meeting
June 06, 2019
Notice of Annual Meeting
April 10, 2019
Venturis appoints Dr. David M. Ornitz and Dr. Arnold I. Chin to its Scientific and Medical Advisory Board
August 30, 2018
Results of July 2018 Shareholders Meeting
July 16, 2018
Trump set to sign "right to try" bill; biotechs rally.
May 30, 2018
Venturis 2016 Annual Shareholders Meeting Results
November 17, 2016
Venturis is pleased to announce that its new home, Texas, is continuing to accelerate its growth in the Biotech industry.
July 12, 2016
Venturis moves Headquarters to Texas
March 8, 2016

Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease, and peripheral artery disease.

Contact Information

2626 Cole Avenue, Suite 300
Dallas, Texas 75204

(972) 904-2029

© Copyright  2023  Venturis Therapeutics  |  All Rights Reserved